PF-Atlas › Clinical Trials › NCT01529853
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis
SAR156597 · Phase 1
Registry ID
NCT01529853
Phase
Phase 1
Status
Completed
Drug / intervention
SAR156597
Sponsor
Sanofi
Start
2012-01
Enrollment
24
Locations
21
About this trial
Primary Objective: To assess in adult patients with Idiopathic Pulmonary Fibrosis (IPF) the safety and tolerability of ascending doses of SAR156597 administered subcutaneously (SC) once weekly over a 6-week period. Secondary Objectives: To assess in adult patients with IPF: * The pharmacodynamic effects of SAR156597, as measured on pulmonary function tests (PFTs), pulse oximetry and patient reported outcome and peripheral blood biomarkers. * The trough plasma concentrations of SAR156597 * The potential immunogenicity of SAR156597.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01529853 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.